1. P450 Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease. (21st January 2022) Authors: Livne-Margolin, M; Ling, D; Attia Konyo, S; Haj, O; Abitbol, C M; Ben-Horin, S; Kopylov, U Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗